$0.90
+0.02 (+1.82%)
Open$0.89
Previous Close$0.88
Day High$0.93
Day Low$0.87
52W High$1.35
52W Low$0.65
Volume—
Avg Volume194.1K
Market Cap29.56M
P/E Ratio—
EPS$-0.23
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,542.9% upside
Current
$0.90
$0.90
Target
$32.64
$32.64
$20.70
$32.64 avg
$34.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 3.49M | 3.43M | 4.58M |
| Net Income | -8,327,916 | -7,363,320 | -1,151,647 |
| Profit Margin | -238.3% | -226.4% | -25.2% |
| EBITDA | -8,136,045 | -7,593,322 | -1,556,423 |
| Free Cash Flow | — | — | -1,101,967 |
| Rev Growth | +1.8% | +1.8% | +24.2% |
| Debt/Equity | 4.08 | 4.08 | 0.58 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |